These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6173369)

  • 1. Alteration of membrane-associated enzymes in drug-resistant sublines of mouse lymphoblastoma L5178Y cells.
    Sugimoto Y; Nishimura T; Suzuki H; Tanaka N
    J Antibiot (Tokyo); 1981 Sep; 34(9):1200-5. PubMed ID: 6173369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
    Tanaka N
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of new antineoplastic antibiotics based on newly discovered action mechanisms].
    Tanaka N
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1094-106. PubMed ID: 6191673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation, drug sensitivity, and some biochemical and genetical properties of macromomycin-resistant mouse lymphoblastoma L5178Y cells.
    Suzuki H; Sugimoto Y; Tanaka K; Nishimura T; Tanaka N
    J Antibiot (Tokyo); 1984 May; 37(5):602-9. PubMed ID: 6547433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug sensitivity and some characteristics of a bleomycin-resistant subline of mouse lymphoblastoma L5178Y cells.
    Suzuki H; Nishimura T; Tanaka N
    J Antibiot (Tokyo); 1981 Sep; 34(9):1210-2. PubMed ID: 6173370
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
    Nishimura T; Suzuki H; Muto K; Tanaka Y; Tanaka N
    J Antibiot (Tokyo); 1980 Jul; 33(7):737-43. PubMed ID: 6931828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of action and resistance of antineoplastic agents].
    Tanaka N
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2245-51. PubMed ID: 6195971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of adriamycin resistance in a subline of mouse lymphoblastoma L5178Y cells.
    Nishimura T; Suzuki H; Muto K; Tanaka N
    J Antibiot (Tokyo); 1979 May; 32(5):518-22. PubMed ID: 583339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of plasma membrane of drug-resistant tumor cells: 230-kilodalton protein identified by monoclonal antibody.
    Sugimoto Y; Suzuki H; Tanaka N
    Biochem Biophys Res Commun; 1983 Aug; 114(3):969-75. PubMed ID: 6577861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.
    Coley HM; Twentyman PR; Workman P
    Biochem Pharmacol; 1989 Dec; 38(24):4467-75. PubMed ID: 2604747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
    Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
    Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity.
    Hori S; Shirai M; Hirano S; Oki T; Inui T; Tsukagoshi S; Ishizuka M; Takeuchi T; Umezawa H
    Gan; 1977 Oct; 68(5):685-90. PubMed ID: 579346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of erythrocyte ATPase activity by aclacinomycin and reverse effects of ascorbate on ATPase activity.
    Kitao T; Hattori K
    Experientia; 1983 Dec; 39(12):1362-4. PubMed ID: 6317432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
    Umezawa K; Kunimoto S; Takeuchi T
    Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
    Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
    Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
    Burres NS; Myers MT; Sartorelli AC
    Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines.
    Kunimoto S; Miura K; Umezawa K; Xu CZ; Masuda T; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1984 Dec; 37(12):1697-702. PubMed ID: 6526737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantability and sensitivity to natural killer cells of aclarubicin-resistant murine lymphoma.
    Sugimoto Y; Hirakawa Y; Tanaka N; Tahara M; Sato I; Nishimura T; Suzuki H; Tanaka N
    Cancer Res; 1986 Nov; 46(11):5646-8. PubMed ID: 3463416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells.
    Ganapathi R; Grabowski D; Schmidt H; Bell D; Melia M
    Cancer Res; 1987 Jul; 47(13):3464-8. PubMed ID: 2884031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures.
    Scott CA; Westmacott D; Broadhurst MJ; Thomas GJ; Hall MJ
    Br J Cancer; 1986 May; 53(5):595-600. PubMed ID: 3718817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.